Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,gmtOffSetMilliseconds,esgPopulated,tradeable,market,exchange,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,priceHint,marketState,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,EX9.DE,1847503000.0,313387008,159288000,,-2015000,,1601000,102351000,257032000,-4607000,-4607000,,,,,,-3616000,270230000,274837000,13198000,2592000,,1601000,1601000,2354103000.0,279355000.0,1911187000.0,56880000.0,2190542000.0,313000.0,9300000.0,-445969000.0,13181000.0,63684000.0,2740000.0,285280000.0,370209000.0,213337000.0,160598000.0,2740000.0,78453000.0,1434265000.0,328860000.0,815285000.0,181273000.0,24757000.0,13821000.0,75812000,13560000,62255000,-2650000,1872000,2791000,99149000,-5441000,39544000,3227000,-2090000,-17690000,39064000,-13557000,1220928000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,0.27531403,16.39 - 16.39,16.345,16.27,16.315,finmb_28338,XETRA,"Exelixis, Inc.",USD,182,44,7200000,False,False,de_market,GER,0.172,6.101,14.970417,1.4195824,0.09482584,17.89412,-1.5041199,-0.08405666,5150000128,2.6864448,15,Europe/Berlin,CEST,16.39,1630510541,0.045000076,16.39,16.39,16.39,166,"EXELIXIS INC.  DL-,01",2,POST,0,2.7749996,0.20381929,13.615 - 22.8,-6.41,-0.28114036,13.615,22.8,1620331200,1635969600,1636401600,95.29069,1.06,,,22.8,13.61,14.97,17.89,182,44,313.39M,,289.17M,2.17%,85.05%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",6.28%,5.37%,1.67%,3.54%,1.03B,3.33,19.10%,953.97M,65.54M,64.77M,0.17,-96.70%,1.19B,3.78,52.84M,2.77,6.72,6.10,192.45M,136.2M,Value,94502,Healthcare,773,4,3,"Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.",Alameda,650 837 7000,CA,4,1609372800,1622505600,2,United States,http://www.exelixis.com,86400,3,1851 Harbor Bay Parkway,650 837 8300,Biotechnology
t-1,EX9.DE,1815429000.0,313387008,154279000,,28127000,,28388000,82439000,261515000,24797000,24797000,,,,,,-261000,270052000,245255000,8537000,3330000,,28388000,28388000,2321895000.0,258220000.0,1879113000.0,41422000.0,2137333000.0,312000.0,,-447570000.0,4476000.0,63684000.0,4476000.0,187109000.0,319217000.0,204658000.0,156711000.0,4476000.0,110394000.0,1445395000.0,330751000.0,887319000.0,165375000.0,20973000.0,23632000.0,-15219000,-5105000,-29509000,-18694000,-9963000,5204000,-14910000,-23898000,33293000,2410000,-8431000,4604000,21390000,-14290000,1240737000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,0.27531403,16.39 - 16.39,16.345,16.27,16.315,finmb_28338,XETRA,"Exelixis, Inc.",USD,182,44,7200000,False,False,de_market,GER,0.172,6.101,14.970417,1.4195824,0.09482584,17.89412,-1.5041199,-0.08405666,5150000128,2.6864448,15,Europe/Berlin,CEST,16.39,1630510541,0.045000076,16.39,16.39,16.39,166,"EXELIXIS INC.  DL-,01",2,POST,0,2.7749996,0.20381929,13.615 - 22.8,-6.41,-0.28114036,13.615,22.8,1620331200,1635969600,1636401600,95.29069,1.06,,,22.8,13.61,14.97,17.89,182,44,313.39M,,289.17M,2.17%,85.05%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",6.28%,5.37%,1.67%,3.54%,1.03B,3.33,19.10%,953.97M,65.54M,64.77M,0.17,-96.70%,1.19B,3.78,52.84M,2.77,6.72,6.10,192.45M,136.2M,Value,94502,Healthcare,773,4,3,"Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.",Alameda,650 837 7000,CA,4,1609372800,1622505600,2,United States,http://www.exelixis.com,86400,3,1851 Harbor Bay Parkway,650 837 8300,Biotechnology
t-2,EX9.DE,1788347000.0,313387008,176762000,,-38021000,,-32040000,88185000,222367000,-42580000,-42580000,,,,,,-5981000,231092000,273672000,8725000,4559000,,-32040000,-32040000,2321441000.0,259012000.0,1852031000.0,35329000.0,2111043000.0,309000.0,,-475958000.0,10043000.0,63684000.0,6239000.0,226723000.0,334046000.0,201343000.0,155678000.0,6239000.0,56385000.0,1407808000.0,356443000.0,853835000.0,170638000.0,19319000.0,47927000.0,-201470000,45242000,-207600000,-3435000,3086000,1744000,-193097000,-5179000,17938000,2355000,-6417000,-45060000,50772000,-6130000,1206465000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,0.27531403,16.39 - 16.39,16.345,16.27,16.315,finmb_28338,XETRA,"Exelixis, Inc.",USD,182,44,7200000,False,False,de_market,GER,0.172,6.101,14.970417,1.4195824,0.09482584,17.89412,-1.5041199,-0.08405666,5150000128,2.6864448,15,Europe/Berlin,CEST,16.39,1630510541,0.045000076,16.39,16.39,16.39,166,"EXELIXIS INC.  DL-,01",2,POST,0,2.7749996,0.20381929,13.615 - 22.8,-6.41,-0.28114036,13.615,22.8,1620331200,1635969600,1636401600,95.29069,1.06,,,22.8,13.61,14.97,17.89,182,44,313.39M,,289.17M,2.17%,85.05%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",6.28%,5.37%,1.67%,3.54%,1.03B,3.33,19.10%,953.97M,65.54M,64.77M,0.17,-96.70%,1.19B,3.78,52.84M,2.77,6.72,6.10,192.45M,136.2M,Value,94502,Healthcare,773,4,3,"Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.",Alameda,650 837 7000,CA,4,1609372800,1622505600,2,United States,http://www.exelixis.com,86400,3,1851 Harbor Bay Parkway,650 837 8300,Biotechnology
t-3,EX9.DE,1769640000.0,313387008,114933000,,80696000,,66821000,59791000,250258000,75534000,75534000,,,,,,13875000,259479000,183945000,9221000,5162000,,66821000,66821000,2269093000.0,213224000.0,1833324000.0,24230000.0,2046548000.0,309000.0,,-443918000.0,22209000.0,63684000.0,7840000.0,210373000.0,527143000.0,142681000.0,148235000.0,7840000.0,52323000.0,1394663000.0,325505000.0,685895000.0,140180000.0,16608000.0,9103000.0,80238000,3202000,73274000,-5148000,-16091000,14000000,169803000,-19148000,101677000,2201000,-2354000,16256000,31642000,-6964000,1251982000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,0.27531403,16.39 - 16.39,16.345,16.27,16.315,finmb_28338,XETRA,"Exelixis, Inc.",USD,182,44,7200000,False,False,de_market,GER,0.172,6.101,14.970417,1.4195824,0.09482584,17.89412,-1.5041199,-0.08405666,5150000128,2.6864448,15,Europe/Berlin,CEST,16.39,1630510541,0.045000076,16.39,16.39,16.39,166,"EXELIXIS INC.  DL-,01",2,POST,0,2.7749996,0.20381929,13.615 - 22.8,-6.41,-0.28114036,13.615,22.8,1620331200,1635969600,1636401600,95.29069,1.06,,,22.8,13.61,14.97,17.89,182,44,313.39M,,289.17M,2.17%,85.05%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",6.28%,5.37%,1.67%,3.54%,1.03B,3.33,19.10%,953.97M,65.54M,64.77M,0.17,-96.70%,1.19B,3.78,52.84M,2.77,6.72,6.10,192.45M,136.2M,Value,94502,Healthcare,773,4,3,"Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.",Alameda,650 837 7000,CA,4,1609372800,1622505600,2,United States,http://www.exelixis.com,86400,3,1851 Harbor Bay Parkway,650 837 8300,Biotechnology
